Chemotherapy in Patients with Organ Dysfunction

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/0-387-31056-8_98
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency

  2004cited by this paper
• [Pharmacokinetics of paclitaxel and carboplatin in a hemodialysis patient with metastatic urothelial carcinoma--a case report].

  2003cited by this paper
• A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.

  2003cited by this paper
• Imatinib administration in two patients with liver metastases from GIST and severe jaundice

  2003cited by this paper
• Carboplatin-based chemotherapy in patients with gynecological malignancies on long-term hemodialysis.

  2003cited by this paper
• Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract

  2003cited by this paper
• Feasibility of combination chemotherapy with cisplatin and etoposide for hemodialysis patients with lung cancer

  2003cited by this paper
• Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.

  2003cited by this paper
• Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment

  2003cited by this paper
• Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme.

  2003cited by this paper
• Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer

  2003cited by this paper
• Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction.

  2003cited by this paper
• Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896)

  2002cited by this paper
• Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients

  2002cited by this paper
• Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study

  2002cited by this paper
• First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.

  2002cited by this paper
• Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function

  2002cited by this paper
• Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum‐based regimens

  2002cited by this paper
• Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction.

  2002cited by this paper
• Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer.

  2002cited by this paper
• Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function

  2002cited by this paper
• A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005)

  2002cited by this paper
• Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic.

  2002cited by this paper
• Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features.

  2001cited by this paper
• Gemcitabine/carboplatin in advanced urothelial cancer.

  2001cited by this paper
• Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer

  2001cited by this paper
• Pharmacokinetics of paclitaxel and cisplatin in a hemodialysis patient with recurrent ovarian cancer

  2001cited by this paper
• Systemic Chemotherapy in Patients With Renal Failure

  2001cited by this paper
• Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point.

  2000cited by this paper
• Phase I clinical trial of liposomal daunorubicin in hepatocellular carcinoma complicating liver cirrhosis.

  2000cited by this paper
• Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

  2000cited by this paper
• [Combined 5-FU and CDDP in a gastric cancer patient undergoing hemodialysis--pharmacokinetics of 5-FU and CDDP].

  2000cited by this paper
• Altered pharmacokinetics and metabolism of CPT-11 in liver dysfunction: a need for guidelines.

  2000cited by this paper
• Pegylated liposomal doxorubicin in treating a case of advanced hepatocellular carcinoma with severe hepatic dysfunction and pharmacokinetic study.

  2000cited by this paper
• [Pharmacokinetics of cisplatin and methotrexate in a patient suffering from advanced ureteral tumor accompanied by chronic renal failure, undergoing combined hemodialysis and systemic M-VAC chemotherapy].

  2000cited by this paper
• [Chemotherapy in hemodialysis patient with metastatic testicular cancer; pharmacokinetics of etoposide and cisplatin].

  2000cited by this paper
• Carboplatin-Gemcitabine Treatment of Patients with Transitional Cell Carcinoma of the Bladder and Impaired Renal Function

  2000cited by this paper
• Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.

  2000cited by this paper
• [Chemotherapy for small-cell lung cancer (SCLC) patients with renal failure].

  2000cited by this paper
• Cancer in patients on dialysis for end-stage renal disease: an international collaborative study.

  1999cited by this paper
• Pharmacokinetics of paclitaxel in an anephric patient

  1999cited by this paper
• Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites.

  1999cited by this paper
• Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function.

  1999cited by this paper
• Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694).

  1998cited by this paper
• Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.

  1998cited by this paper
• A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum

  1998cited by this paper
• Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen.

  1998cited by this paper
• Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel.

  1998cited by this paper
• Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.

  1997cited by this paper
• Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports.

  1997cited by this paper
• Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function.

  1996cited by this paper
• Phase I and pharmacologic study of topotecan in patients with impaired renal function.

  1996cited by this paper
• Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy.

  1996cited by this paper
• [Pharmacokinetics of carboplatin in a patient under hemodialysis].

  1994cited by this paper
• Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.

  1994cited by this paper
• Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency.

  1994cited by this paper
• Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group.

  1994cited by this paper
• Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters.

  1992cited by this paper
• Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests.

  1992cited by this paper
• Changes in the clearance of total and unbound etoposide in patients with liver dysfunction.

  1990cited by this paper
• Etoposide kinetics in patients with obstructive jaundice.

  1990cited by this paper
• Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

  1989cited by this paper
• M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.

  1988cited by this paper
• Phase I clinical and pharmacokinetic study of taxol.

  1987cited by this paper
• High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial.

  1987cited by this paper
• Etoposide pharmacokinetics in patients with normal and abnormal organ function.

  1986cited by this paper
• Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function.

  1986cited by this paper
• Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.

  1985cited by this paper
• Acute doxorubicin toxicity relationship to pretreatment liver function, response, and pharmacokinetics in patients with acute nonlymphocytic leukemia

  1984cited by this paper
• Pharmacokinetic studies of 4'-epi-doxorubicin in cancer patients with normal and impaired renal function and with hepatic metastases.

  1982cited by this paper
• The pharmacokinetics of vincristine in man:

  1982cited by this paper
• Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis.

  1980cited by this paper
• Adriamycin chemotherapy—efficacy, safety, and pharmacologic basis of an intermittent single high‐dosage schedule

  1974cited by this paper

• Feasibility and Outcomes of Ureteroureterostomy and Extravesical Ureteroneocystostomy as Part of Radical Surgery for Infiltrating Gynecologic Disease

  2013cites this paper
• Laboratory monitoring in oncology

  2006cites this paper
• BASIC REVIEW Laboratory monitoring in oncology

  2006cites this paper